La glycoprotéine P, une source d’interactions médicamenteuses

Juliano, 1976, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim Biophys Acta, 455, 152, 10.1016/0005-2736(76)90160-7 Biedler, 1970, Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies, Cancer Res, 30, 1174 Zhang, 1999, Characterization of human small intestinal cytochromes P-450, Drug Metab Dispos, 27, 804 Su, 1996, Inhibition of the intestinal digoxin absorption and exsorption by quinidine, Drug Metab Dispos, 24, 142 Jeffrey, 2013, The P-glycoprotein transport system and cardiovascular drugs, J Am Coll Cardiol, 61, 2495, 10.1016/j.jacc.2013.02.058 Greiner, 1999, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J Clin Invest, 104, 147, 10.1172/JCI6663 Base de données publique des médicaments. Résumé des caractéristiques du produit et notice. ELIQUIS 5 mg, comprimé pelliculé. http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61902218. Terkeltaub, 2011, Novel evidence based colchicine dose reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors, Arthritis Rheum, 63, 2226, 10.1002/art.30389 The International Transporter Consortium, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028